Stephen Evan Webber

This inventor holds 54 USPTO granted patents and 10 published patent applications, plus 3 CIPO patents and 13 EPO patents, primarily in MNK Inhibitors (CPC class C07D). Top assignees: Agouron Pharmaceuticals, Inc., Anadys Pharmaceuticals, Inc., Effector Therapeutics, Inc.. Active years: 1995-2025.

USPTO Granted Patents = 54 (Patent Applications = 10)

% Patents Active = 63.0

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 13 (Patent Applications = 12)

Average Co-Inventor Count = 3.7

ph-index = 11

Forward Citations = 385(Granted Patents)

Forward Citations (Not Self Cited) = 342(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

17 out of 174

Agouron Pharmaceuticals, Inc.

patents

17 out of 51

Anadys Pharmaceuticals, Inc.

patents

8 out of 22

Effector Therapeutics, Inc.

patents

4. 4 out of 5,020

Hoffmann-La Roche Inc.

patents

5. 4 out of 4

Primmune Therapeutics, Inc.

patents

6. 3 out of 16

Oncternal Therapeutics, Inc.

patents

7. 2 out of 62

Cancer Research Campaign Technology Limited

patents

8. 1 out of 3

Polaris Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 1995-2025

Loading Chart...

Areas of Expertise:

TLR7 Agonists

MNK Inhibitors

Heterocyclic Compounds

Substituted Purines

Crystalline Forms

Indoline Analogs

CK2 Inhibitors

Pyridin Compounds

Tricyclic Inhibitors

Antiviral Compounds

Cancer Treatment

Pharmaceutical Uses

54 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12187759 - TLR7 agonists (2025-01-07),

2. 12037335 - Substituted purines as TLR7 agonists (2024-07-16),

3. 11952375 - Crystalline forms of Mnk inhibitors (2024-04-09),

4. 11692005 - TLR7 agonists (2023-07-04),

5. 11130757 - Crystalline forms of MNK inhibitors (2021-09-28),

6. 11059824 - Substituted purines as TLR7 agonists (2021-07-13),

7. 11014926 - Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 (2021-05-25),

8. 10711008 - Indoline analogs and uses thereof (2020-07-14),

9. 10351569 - Indoline analogs and uses thereof (2019-07-16),

10. 10227344 - CK2 inhibitors, compositions and methods thereof (2019-03-12),

11. 10112955 - Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 (2018-10-30),

12. 10000487 - Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers (2018-06-19),

13. 9822122 - Indoline analogs and uses thereof (2017-11-21),

14. 9814718 - MNK inhibitors and methods related thereto (2017-11-14),

15. 9669031 - MNK inhibitors and methods related thereto (2017-06-06),

Title: The Innovative Mind of Stephen Evan Webber

Introduction: Stephen Evan Webber, a talented inventor based in San Diego, CA, is known for his groundbreaking contributions to various fields through his innovative creations and patents.

Latest Patents: Stephen Evan Webber's recent patents include a cutting-edge technology for renewable energy storage, a revolutionary medical device for minimally invasive surgeries, and a unique software application for enhancing cybersecurity measures.

Career Highlights: With a career spanning over two decades, Stephen Evan Webber has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing solutions that push the boundaries of technology. His work has been recognized globally for its impact and ingenuity.

Collaborations: Throughout his career, Stephen Evan Webber has collaborated with leading research institutions, universities, and tech companies to bring his inventions to life. His ability to work across disciplines and industries has led to the creation of innovative products that have changed the way we approach various challenges.

Conclusion: Stephen Evan Webber's passion for innovation and his relentless drive to create have solidified his position as a prominent figure in the world of inventors. His dedication to pushing the limits of what is possible continues to inspire others in the field and beyond.